Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00724984 · OUTCOME

Phase I (Dose Escalation Phase): MTD and DLTs of PCI-24781 Administered Twice Daily (BID) Measure: Disease Response

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma · Source last updated 2014-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
From the Date of PCI-24781 first administration to Cycle 2 Day 1

What was measured

Number of patients experienced DLT in each cohort

Groups in this outcome

Cohort 1(30 mg/m2, BID, 5days/wk)/Phase I

Not reported

Cohort 2(45 mg/m2, BID, 5days/wk)/Phase I

Not reported

Cohort 3(45 mg/m2, BID, 7days/wk)/Phase I

Not reported

Cohort 4(60 mg/m2, BID, 7days/wk)/Phase I

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 1(30 mg/m2, BID, 5days/wk)/Phase I3
Cohort 2(45 mg/m2, BID, 5days/wk)/Phase I7
Cohort 3(45 mg/m2, BID, 7days/wk)/Phase I3
Cohort 4(60 mg/m2, BID, 7days/wk)/Phase I8

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 1(30 mg/m2, BID, 5days/wk)/Phase I0Not reportedNot reportedNot reportedNot reported
Cohort 2(45 mg/m2, BID, 5days/wk)/Phase I3Not reportedNot reportedNot reportedNot reported
Cohort 3(45 mg/m2, BID, 7days/wk)/Phase I0Not reportedNot reportedNot reportedNot reported
Cohort 4(60 mg/m2, BID, 7days/wk)/Phase I2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      7
    3. group Id
      OG002
      value
      3
    4. group Id
      OG003
      value
      8
    units
    Participants
description
Number of patients experienced DLT in each cohort
groups
  1. id
    OG000
    title
    Cohort 1(30 mg/m2, BID, 5days/wk)/Phase I
  2. id
    OG001
    title
    Cohort 2(45 mg/m2, BID, 5days/wk)/Phase I
  3. id
    OG002
    title
    Cohort 3(45 mg/m2, BID, 7days/wk)/Phase I
  4. id
    OG003
    title
    Cohort 4(60 mg/m2, BID, 7days/wk)/Phase I
param Type
NUMBER
reporting Status
POSTED
time Frame
From the Date of PCI-24781 first administration to Cycle 2 Day 1
title
Phase I (Dose Escalation Phase): MTD and DLTs of PCI-24781 Administered Twice Daily (BID) Measure: Disease Response
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice